Citadel Advisors
USNA icon

Citadel Advisors’s Usana Health Sciences USNA Stock Holding History

Citadel Advisors’s Portfolio USNA Stock Details USNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,200
Closed -$391K – 14143
2025
Q3 		$391K Buy
14,200
+6,500
+84% +$200K ﹤0.01% 9719
2025
Q2 		$235K Buy
7,700
+1,600
+26% +$45.4K ﹤0.01% 10350
2025
Q1 		$165K Buy
6,100
+4,700
+336% +$149K ﹤0.01% 10724
2024
Q4 		$50.2K Sell
1,400
-2,300
-62% -$86K ﹤0.01% 12384
2024
Q3 		$140K Buy
3,700
+500
+16% +$20.5K ﹤0.01% 10651
2024
Q2 		$145K Sell
3,200
-3,500
-52% -$161K ﹤0.01% 10396
2024
Q1 		$325K Buy
6,700
+5,700
+570% +$279K ﹤0.01% 9278
2023
Q4 		$53.6K Sell
1,000
-5,200
-84% -$263K ﹤0.01% 11715
2023
Q3 		$363K Sell
6,200
-3,900
-39% -$244K ﹤0.01% 8756
2023
Q2 		$637K Buy
10,100
+7,500
+288% +$478K ﹤0.01% 7407
2023
Q1 		$164K Hold
2,600
– – ﹤0.01% 10492
2022
Q4 		$138K Buy
+2,600
New +$141K ﹤0.01% 10735
2021
Q4 		– Sell
-3,100
Closed -$286K – 14802
2021
Q3 		$286K Sell
3,100
-2,700
-47% -$260K ﹤0.01% 11146
2021
Q2 		$594K Buy
5,800
+800
+16% +$80.3K ﹤0.01% 9647
2021
Q1 		$488K Buy
+5,000
New +$455K ﹤0.01% 9728
2020
Q4 		– Sell
-3,800
Closed -$280K – 11552
2020
Q3 		$280K Sell
3,800
-5,000
-57% -$401K ﹤0.01% 8245
2020
Q2 		$646K Buy
8,800
+4,400
+100% +$345K ﹤0.01% 6612
2020
Q1 		$254K Buy
+4,400
New +$306K ﹤0.01% 7612
2019
Q4 		– Sell
-5,200
Closed -$356K – 9809
2019
Q3 		$356K Sell
5,200
-900
-15% -$60.4K ﹤0.01% 7309
2019
Q2 		$485K Buy
6,100
+2,400
+65% +$190K ﹤0.01% 6865
2019
Q1 		$310K Buy
+3,700
New +$386K ﹤0.01% 7572
2018
Q4 		– Sell
-3,500
Closed -$422K – 9795
2018
Q3 		$422K Buy
3,500
+1,300
+59% +$161K ﹤0.01% 6978
2018
Q2 		$254K Buy
+2,200
New +$241K ﹤0.01% 7498

Other funds holding USNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Pzena Investment Management
Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's USNA Position: Q1 2026 in Review

Citadel Advisors reduced its Usana Health Sciences (USNA) stake by 73% in Q1 2026, selling an estimated $2.19M and leaving 41,148 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #8442.

Citadel Advisors first reported a position in USNA in Q2 2013 and has held it in 45 quarters since. The position peaked at $13.8M in Q1 2019. 139 funds tracked by Wall St. Rank hold USNA as of Q1 2026.

  • Citadel Advisors held 41,148 shares of Usana Health Sciences worth $719K as of Q1 2026.
  • Citadel Advisors sold 110,268 Usana Health Sciences shares in Q1 2026, an estimated $2.19M.
  • Usana Health Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8442 holding.
  • Citadel Advisors first reported a position in Usana Health Sciences in Q2 2013 and has held it in 45 quarters since.
  • Citadel Advisors's Usana Health Sciences position peaked at $13.8M in Q1 2019.
  • 139 funds tracked by Wall St. Rank held Usana Health Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.